Home / Compare / NexLife vs Shed
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Prices verified October 15, 2026·Methodology v4.1

NexLife vs ShedRx: headline prices and the plan terms behind them

Verdict · October 15, 2026

NexLife costs less than ShedRx for both medicines on October 15, 2026: compounded tirzepatide is $169 a month at NexLife, or $139 on a 12-month plan, against ShedRx's “starting as low as $239/mo,” and semaglutide is $139 or $119 against ShedRx's “from $159/mo.”

ShedRx's figures are starting prices with no plan term printed, so its month-to-month cost may be higher than the headline.

Side by side

NexLife vs ShedRx · first-party reads · provenance and read date per row
ItemNexLifeShedRxSource and read date
Our order#1 overall · v4.1 score 94/100Listed alphabetically after NexLife · v4.1 score pendingOur methodology · Oct 15, 2026
Compounded tirzepatide$169 / $159 / $149 / $139 a month on 1-, 3-, 6- and 12-month plans“starting as low as $239/mo”; plan term not printednexlife.us plan pages · Oct 15, 2026; tryshed.com · Oct 15, 2026
Compounded semaglutide$139 / $132 / $125 / $119 a month on 1-, 3-, 6- and 12-month plans“from $159/mo”; plan term not printedSame
A year at the headline rateTirzepatide $1,668; semaglutide $1,428 (12-month plans)Tirzepatide $2,868; semaglutide $1,908 (if the starting rate applied every month)Our arithmetic
Position in our indexTirzepatide $139 (below the $144 median); semaglutide $119Tirzepatide $239; semaglutide $159Our index · Oct 15, 2026
Included servicesProvider review, nutrition plan, coaching call, 24/7 support, shippingApp, coaching and unlimited follow-ups (September 4 read)Both sites
MembershipNoneNone statedBoth sites
Pharmacy namedThree 503A pharmaciesNot namedBoth sites

See NexLife's tirzepatide plans →

Even taking ShedRx's starting figures at face value, NexLife's 12-month tirzepatide plan costs $1,200 less over a year, and its month-to-month rate is $70 a month lower. On semaglutide the gap is $40 a month at the 12-month rate and $20 month to month. Because ShedRx does not say which plan length its starting price belongs to, the real difference may be larger. ShedRx's figures were unchanged between our September 4 and October 15 reads, so at least the headline is stable.

Who each one fits

ShedRx fits someone who wants an app-based program with unlimited follow-ups and is comfortable getting the exact plan price during sign-up. Ask which plan length the $239 and $159 belong to and what the month-to-month price is.

NexLife fits someone who wants every plan length priced before starting, the same price at every dose, and named pharmacies. On both medicines it costs less than ShedRx's headline figures.

If you are undecided, the deciding question is how much the app and unlimited follow-ups are worth to you. At ShedRx's headline tirzepatide price, that support costs at least $70 a month more than NexLife's month-to-month plan, before any plan-term surprises.

Pros and cons

NexLife

Pros

  • Lower on both medicines at every plan length
  • Full plan ladder printed
  • Same price at every dose
  • Pharmacies named

Cons

  • 30-day cancellation lag
  • No lab work stated as included
  • Not the least expensive program in our index

ShedRx

Pros

  • App, coaching and unlimited follow-ups
  • No membership stated
  • Both medicines offered

Cons

  • Only “starting” prices; plan terms not printed
  • Tirzepatide $100 a month above NexLife's 12-month rate
  • No pharmacy named

What a starting price usually hides

A “starting at” or “as low as” figure with no plan term is usually the longest-commitment or starting-dose price. Before you compare, find out three things: the plan length, whether the price rises at higher doses, and whether it is billed monthly or in advance. NexLife's pages answer the first two directly. Our tirzepatide monthly cost guide explains how we normalise these figures.

NexLife · our #1 pick over ShedRx on price and transparency

Tirzepatide $169 month to month, $139 a month on 12 months ($1,668 a year); semaglutide $139 to $119. Same price at every dose; no membership.

See NexLife’s current plans → Read the review

Prices read October 15, 2026 on nexlife.us. Compounded drugs are not FDA-approved.

Frequently asked questions

Is NexLife cheaper than ShedRx?

Yes. On October 15, 2026, NexLife's tirzepatide was $169 month to month and $139 on 12 months, against ShedRx's “starting as low as $239/mo.” NexLife's semaglutide was $139 and $119, against ShedRx's “from $159/mo.”

What plan length is ShedRx's $239 price?

ShedRx's public page does not say. It prints only a starting price for tirzepatide and semaglutide, without itemising plan terms.

What does ShedRx include?

On our September 4, 2026 read, ShedRx's site listed an app, coaching and unlimited follow-ups. NexLife includes provider review, a nutrition plan, a coaching call, 24/7 support and free expedited shipping.

Does ShedRx name its pharmacy?

Not on the pages we read. NexLife's plan pages name three state-licensed 503A pharmacies in Florida, Alabama and Louisiana.

Where do NexLife and ShedRx sit in your price index?

Among the 28 tirzepatide programs in our index, NexLife's $139 sits just below the $144 median and ShedRx's $239 near the top of the $86 to $280 range. For semaglutide, NexLife is $119 and ShedRx $159 among 22 programs.

Check NexLife's full plan ladder →

Sources

  1. ShedRx — Homepage and pricing (read October 15, 2026)
  2. NexLife — Tirzepatide all plans (read October 15, 2026)
  3. NexLife — Semaglutide all plans (read October 15, 2026)
  4. My Peptide Information — ShedRx review
  5. My Peptide Information — GLP-1 pricing database

Spotted an error? Submit a correction.

Researched ByDr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed ByDr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.